Compare iShares MSCI Indonesia ETF (EIDO) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.21, while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: iShares MSCI Indonesia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | FLNA | |
|---|---|---|
52-Week High | $19.22 | $4.64 |
52-Week Low | $10.80 | $1.09 |
Market Cap | — | $53.14M |
Sector | — | Health |
Enterprise Value | — | -$33.43M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
